Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Implications of KRAS mutation status for the treatment of metastatic colorectal cancer.

Targeted oncology - 1 Dec 2009

Ciardiello Fortunato, Tejpar Sabine, Papamichael Demetris

Abstract excerpt

Targeted agents have become an integral part of the treatment of a number of malignant diseases and regimens containing agents that disrupt the epidermal growth factor receptor (EGFR) signaling pathway are now considered a standard therapeutic approach for a range of tumor types. Recently, the mu...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Monoclonal, Humanized
Share to Camptothecin
Share to Cetuximab

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Delivery Systems

Share to Irinotecan

Share to Organoplatinum Compounds

Share to Oxaliplatin

Share to ras Proteins

Source

Identifiers

PMID: 19915942
DOI: 10.1007/s11523-009-0129-6

Genes

KRAS
EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-19915942-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Implications of KRAS mutation status for the treatment of metastatic colorectal cancer.PMID 19915942Read ↗

KRAS mutation in metastatic colorectal cancer and its impact on the use of EGFR inhibitors.Semantic proximity Read ↗

Impact of cetuximab in current treatment of metastatic colorectal cancer.Semantic proximity Read ↗

KRAS testing in metastatic colorectal cancer: implications on the use of biologic agents.Semantic proximity Read ↗

The treatment of colorectal carcinoma with monoclonal antibodies: the importance of KRAS mutation analysis and EGFR status.Semantic proximity Read ↗

KRAS testing and its importance in colorectal cancer.Semantic proximity Read ↗

KRAS status predicts response to cetuximab for metastatic colorectal cancer.Semantic proximity Read ↗

Therapeutic implications of resistance to molecular therapies in metastatic colorectal cancer.Semantic proximity Read ↗

Predictive and prognostic value of KRAS mutations in metastatic colorectal cancer patients treated with cetuximab: a meta-analysis of 22 studies.Semantic proximity Read ↗

KRAS mutations and sensitivity to anti-EGFR monoclonal antibodies in metastatic colorectal carcinoma: an open issue.Semantic proximity Read ↗

KRAS status and resistance to epidermal growth factor receptor tyrosine-kinase inhibitor treatment in patients with metastatic colorectal cancer: a meta-analysis.Semantic proximity Read ↗

EGFR and KRAS in colorectal cancer.Semantic proximity Read ↗

Cetuximab in metastatic colorectal cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.